Sirukumab

Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).[2]

Sirukumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL6
Clinical data
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6450H9926N1690O1998S46
Molar mass144588.95 g·mol−1
 NY (what is this?)  (verify)

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.[3]

Clinical trials

Rheumatoid arthritis

It has started clinical trials.[4] and reported some phase II results.[3]

In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[5] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[6]

Other

The drug was previously under development for the treatment of depression.[7]

See also

References
  1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
  2. Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE (July 2018). "Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018". Expert Review of Clinical Immunology. 14 (7): 539–547. doi:10.1080/1744666X.2018.1487291. PMID 29925278.
  3. "Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis". PR News Wire. Cision. 25 May 2011.
  4. Clinical trial number NCT00718718 for "A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy" at ClinicalTrials.gov
  5. House DW. "Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis". Seeking Alpha.
  6. "IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab". January 2017.
  7. "Sirukumab - Janssen Biotech". AdisInsight. Springer Nature Switzerland AG.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.